文献速递免疫规划传染病防控与疫情报告

疫苗错配的乙型流感优势季流感疫苗有效性评估

Influenza vaccine effectiveness against laboratory-confirmed influenza in a vaccine-mismatched influenza B-dominant season.
PubMed 文献 · Vaccine · 2020-11-23

本研究采用检测阴性设计评估2017-2018年以色列流感季灭活疫苗有效性。该季以乙型Yamagata为主,疫苗株为乙型Victoria系。结果显示甲型流感全年龄VE为46.6%,0.5-14岁儿童达72.9%;乙型流感全年龄VE仅23.2%,与疫苗株错配有关。

要点

  • 甲型流感疫苗有效性中等偏高,儿童0.5-14岁VE达72.9%。
  • 乙型流感全年龄VE仅23.2%,95%CI含零,与疫苗株错配相关。
  • 儿童和青少年接种季节性流感疫苗具有较好保护支持。

核心结论

  • 2017-2018年以色列流感季甲型流感疫苗有效性中等偏高,儿童和青少年保护较好。
  • 乙型流感疫苗有效性低,很可能由乙型Victoria系疫苗株与流行Yamagata系错配所致。

研究设计与样本

  • 采用检测阴性设计的回顾性研究,评估2017-2018年流感季灭活流感疫苗有效性。
  • 共获取1453例社区流感样病例标本,其中1320例适合疫苗有效性分析。

主要发现

  • 610例(42.0%)标本流感阳性,其中乙型69.7%、甲型H1N1pdm09 17.2%、甲型H3N2 13.4%。
  • 分子特征化的乙型流感中98.6%属于Yamagata系。
  • 接种者中90.6%接种含乙型Victoria系病毒的三价灭活疫苗。
  • 甲型流感全年龄VE为46.6%(95%CI 10.4-68.2%),0.5-14岁儿童VE最高为72.9%(95%CI 31.9-89.2%)。
  • 乙型流感全年龄VE为23.2%(95%CI -10.1-46.4%),年龄别分析未见显著VE估计。

临床怎么用

  • 儿童和青少年接种季节性流感疫苗可获较好甲型流感保护,支持低龄人群接种。
  • 疫苗株与流行株错配时乙型流感保护有限,应关注疫苗株匹配性监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2017-2018 influenza season in Israel was characterized by the predominance of influenza B Yamagata, with a lesser circulation of influenza A(H1N1)pdm09 and influenza A(H3N2). We estimated vaccine effectiveness (VE) of the inactivated influenza vaccine which was selected for use that season. METHODS: End-of-season VE and 95% confidence intervals (CI) against laboratory-confirmed influenza-like illness (ILI) were estimated by means of the test-negative design. Age-specific VE analysis was carried out using a moving age interval. RESULTS: Specimen were obtained from 1,453 community ILI patients; 610 (42.0%) were influenza-positive, among which 69.7% were B, 17.2% A(H1N1)pdm09 and 13.4% A(H3N2). A 98.6% of molecularly characterized influenza B belonged to the Yamagata lineage. Of the sampled individuals, 1320 were suitable for VE analysis. Of those vaccinated, 90.6% received the inactivated trivalent influenza vaccine (TIV) containing a Victoria lineage influenza B-like virus. VE against influenza A differed by age, with the highest VE of 72.9% (95%CI 31.9-89.2%) observed in children 0.5-14 years old, while all ages VE was 46.6% (95%CI 10.4-68.2%). All ages VE against influenza B was 23.2% (95%CI -10.1-46.4%) with age-specific analysis showing non-significant VE estimates. Utilizing a moving age interval of 15 years, afforded a detailed age-specific insight into influenza VE against the influenza viruses circulating during the 2017-2018 season. CONCLUSIONS: The moderate-high 2017-2018 influenza A VE among children and adolescents, supports seasonal influenza vaccination at a young age. The low VE against influenza B in Israel, is most likely the result of influenza B/TIV-mismatch.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Drori Y, Pando R, Sefty H, et al. Influenza vaccine effectiveness against laboratory-confirmed influenza in a vaccine-mismatched influenza B-dominant season. Vaccine. 2020. PMID: 33243633. doi:10.1016/j.vaccine.2020.10.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。